Explore this article's sources with AI
Follow PeptideMethods on Google
MASLD Screening Without a Liver Biopsy
A new review explains how FIB-4 screens for MASLD and MASH in primary care, now that semaglutide and resmetirom can treat confirmed cases.
Why we wrote this. Two drugs now treat confirmed MASH, which makes knowing who to screen with FIB-4 a genuinely practical primary care question.
In this article (6 sections)
A liver biopsy is rarely the first move anymore, according to a new plain-language review that argues most at-risk patients can be flagged without one. Published in Postgraduate Medicine, the review lays out how a low-cost, blood-based score can screen for metabolic dysfunction-associated steatotic liver disease (MASLD) and its more advanced form, metabolic dysfunction-associated steatohepatitis (MASH), in a routine visit, before a specialist or an imaging suite gets involved. [1]
What MASLD and MASH mean in plain English
MASLD is the current name for fat buildup in the liver that is not caused by heavy alcohol use. It travels with obesity, type-2 diabetes, and other markers of metabolic dysfunction, which is why the name replaced the older term nonalcoholic fatty liver disease. MASH is the more advanced stage: the fat has triggered inflammation and early scarring, known as fibrosis, in liver tissue. Left unchecked, MASH can progress toward cirrhosis and liver failure. [1] Most people with either condition have no symptoms, which is exactly why a screening tool that works during a routine visit matters.
FIB-4: a score built from numbers your clinic already has
The first-line tool the review points to is the Fibrosis-4 Index, or FIB-4. It combines four values that most clinics already have on file: age, platelet count, and two liver enzymes, AST and ALT. [3] A clinician can calculate it from a standard metabolic panel and complete blood count without ordering anything new. A low score is reassuring. The American Association for the Study of Liver Diseases notes that a FIB-4 under 1.3 can generally rule out advanced fibrosis and spare a patient an unnecessary referral. [3] A high score does not diagnose MASH on its own. It flags who should move to a second-tier test.
What happens after a high score
Patients who cross the FIB-4 threshold typically move to a second-tier check: transient elastography, which estimates liver stiffness with sound waves, or a follow-up blood panel such as the Enhanced Liver Fibrosis score. [1] Only patients whose results stay concerning after that second step usually go on to a liver biopsy, which remains the most definitive test but carries real downsides. It is invasive, can be uncomfortable, and carries a small risk of bleeding or infection, which is the whole reason the sequential, non-invasive approach exists in the first place.
Why more clinics are ordering this test now
Two medicines now give clinicians something to do once MASH is confirmed, and that is part of why the review argues for wider FIB-4 use in primary care. Resmetirom, an oral liver-directed drug sold as Rezdiffra, received accelerated FDA approval in March 2024 for adults with MASH and moderate to advanced fibrosis. [2] In August 2025 the FDA added a second option. Semaglutide, the GLP-1 receptor agonist sold as Wegovy for weight management, was approved for the same fibrosis stages after a late-stage trial found that a majority of patients on the drug saw their steatohepatitis resolve without their fibrosis getting worse. [4]
The same semaglutide molecule already carries approvals for type-2 diabetes (as Ozempic and Rybelsus) and chronic weight management (as Wegovy), so the MASH approval extends an existing prescription-only medicine into a new indication rather than introducing a new compound. Both liver drugs are for a confirmed diagnosis, not a general recommendation. Whether a specific patient is a candidate for either one is a conversation for a clinician who has reviewed the case, not something FIB-4 alone decides.
What this means if you are already on a GLP-1 drug
If you take semaglutide or a related medicine for diabetes or weight management, the review's point is not that you need a separate liver drug. It is that MASLD and MASH are common enough in people with obesity or type-2 diabetes that asking a clinician whether your FIB-4 has ever been calculated is a reasonable, low-effort question. [1] The overlap between the population already prescribed GLP-1 drugs and the population at risk for MASLD is a large part of why the authors frame this as a primary care question, not a specialist-only one.
What we don't yet know
FIB-4 is not perfect. The AASLD's own guidance flags that the score can miss patients with meaningfully elevated liver stiffness, and it recommends extra caution when interpreting results in people with diabetes or obesity, which happens to be the population most likely to be screened in the first place. [3] Sensitivity for detecting real fibrosis has been reported in the high 50s percent in some analyses, meaning a meaningful share of people who do have the disease will still score below the cutoff and need a clinician to stay alert to other risk factors. [1] The review argues that broader primary care adoption is still worth pursuing because the alternative, no routine screening at all, misses far more cases. The tradeoff is a tool that is good at reassurance and only fair at catching every case, and that limitation belongs in the conversation, not just the footnotes.
Frequently asked
What is the difference between MASLD and MASH?
MASLD (metabolic dysfunction-associated steatotic liver disease) is the umbrella term for liver fat linked to metabolic risk factors such as obesity and type-2 diabetes. MASH (metabolic dysfunction-associated steatohepatitis) is the more advanced stage, where the fat is accompanied by inflammation and early scarring. MASH carries a higher risk of progressing to cirrhosis.
What is FIB-4 and how is it calculated?
FIB-4 (Fibrosis-4 Index) is a score built from four values most clinics already collect: a patient's age, platelet count, and two liver enzymes, AST and ALT. A clinician can calculate it from a routine blood panel without ordering a new test. A low score helps rule out advanced fibrosis; a high score flags who should move on to imaging or a second blood-based test.
Does semaglutide treat fatty liver disease?
Semaglutide, sold as Wegovy for weight management, received FDA approval in August 2025 for noncirrhotic MASH with moderate to advanced fibrosis, based on a late-stage trial showing improvement in liver inflammation and fibrosis. It is a prescription medicine for a confirmed MASH diagnosis, not a general fatty-liver treatment, and the decision to use it rests with a treating clinician.
Should I ask my doctor for a FIB-4 test?
If you have obesity, type-2 diabetes, or other metabolic risk factors and have never had your liver fibrosis risk assessed, asking whether a FIB-4 calculation makes sense is a reasonable question for a primary care visit. FIB-4 has real limitations, including reduced sensitivity in some patients with diabetes or obesity, so a low score does not rule out every case on its own.
Sources
- [1]Kugelmas M, Chao AM. Plain language review: non-invasive screening for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) in primary care. Postgrad Med. 2026 Sep 18. PMID 42757508Tier 1 · primary↩
- [2]FDA Drug Trials Snapshot: REZDIFFRA (resmetirom), approved 14 March 2024 for MASH with liver fibrosisTier 1 · primary↩
- [3]AASLD Liver Fellow Network: why non-invasive risk scores such as FIB-4 are used in clinical practiceTier 2 · expert↩
- [4]Healio Gastroenterology: FDA approves Wegovy (semaglutide) for certain adults with noncirrhotic MASHTier 2 · expert↩
No revisions yet. First published .